AG
BHVN

Algert Global’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Algert Global’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-19,192
Closed -$2.9M – 1357
2022
Q3 		$2.9M Buy
19,192
+5,349
+39% +$793K 0.18% 165
2022
Q2 		$2.02M Buy
13,843
+1,390
+11% +$178K 0.15% 187
2022
Q1 		$1.48M Buy
12,453
+9,734
+358% +$1.21M 0.1% 352
2021
Q4 		$375K Sell
2,719
-1,530
-36% -$195K 0.05% 649
2021
Q3 		$590K Buy
+4,249
New +$531K 0.08% 472
2021
Q1 		– Sell
-10,886
Closed -$933K – 584
2020
Q4 		$933K Buy
+10,886
New +$922K 0.27% 143
2020
Q2 		– Sell
-7,303
Closed -$249K – 533
2020
Q1 		$249K Buy
+7,303
New +$334K 0.11% 277

Other funds holding BHVN

LIP
Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $404M AUM 19.8% 1-Year Est. Return

Algert Global's BHVN Position: Q4 2022 in Review

Algert Global sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 19,192 shares — an estimated $2.9M sold.

Algert Global first reported a position in BHVN in Q1 2020 and held it in 7 quarters. The position peaked at $2.9M in Q3 2022. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • Algert Global reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • Algert Global sold 19,192 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $2.9M.
  • Algert Global first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q1 2020 and held it in 7 quarters.
  • Algert Global's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $2.9M in Q3 2022.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on Algert Global's 13F filing for Q4 2022, filed 14 Feb 2023.